Interleukin 2 News and Research

RSS

Novel sortase-based techniques allow modification of a large variety of different proteins

Whitehead Institute scientists have created a method that site-specifically modifies proteins to exert control over their properties when administered therapeutically. The technique should be useful to increase potency, slow metabolism, and improve thermal stability of therapeutically useful proteins, such as interferon alpha 2 (IFN-alpha 2), which is used to treat variety of diseases, including leukemia, melanoma, and chronic hepatitis C.

10 Mar 2011

EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML

EpiCept Corporation today announced the Company has identified a statistically significant survival benefit in a subgroup of Acute Myeloid Leukemia patients in its previous Phase III trial with Ceplene administered with low-dose interleukin-2.

3 Mar 2011

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

An experimental drug that targets a brain system that controls inflammation might help preserve neurological function in people who survive sudden cardiac arrest, new research suggests.

2 Mar 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

EpiCept 2010 fourth quarter net loss is $0.06 per share

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2010, and provided an update on its key business initiatives.

24 Feb 2011

New research: Reovirus infected melanoma cells secrete proteins that can kill cancer

Reoviruses are successfully being used in clinical trials to treat patients with cancer. Not only does the virus cause cancer cells to die, it also forces them to release pro-inflammatory chemokines and cytokines, which in turn causes the patient's immune system to attack the disease.

21 Feb 2011

Emotional response to challenging situations predict body's response to stress

Your emotional response to challenging situations could predict how your body responds to stress, according to research published this month in the journal Brain, Behavior, and Immunity.

18 Feb 2011

Study confirms anti-inflammatory properties of Oligonol in humans

A recently published study in Nutrition Research and Practice has verified the anti-inflammatory effects in humans of Oligonol® lychee fruit polyphenol. The study examined Oligonol intake on cortisol and related cytokines in healthy young men. Both cortisol and cytokine concentrations are inflammatory markers known to increase when stress such as exercise is caused on the body.

15 Feb 2011

Blocking interleukin 15 may help restore oral tolerance to gluten

Blocking a factor that can activate the human immune response against intestinal bacteria or certain foods could prevent the development of celiac disease in those most at risk, researchers report in the journal Nature.

11 Feb 2011

Seaweed microsponges may help diagnose many diseases quickly, at far lower cost

Microsponges derived from seaweed may help diagnose heart disease, cancers, HIV and other diseases quickly and at far lower cost than current clinical methods. The microsponges are an essential component of Rice University's Programmable Bio-Nano-Chip (PBNC) and the focus of a new paper in the journal Small.

9 Feb 2011

Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations' (MCOs) pharmacy directors indicate that Abbott/Eisai's Humira and Amgen/Pfizer/Stiefel/Takeda's Enbrel have the best overall clinical profile when compared to other currently available agents.

9 Feb 2011

Technique that cleared mouse of HIV-like virus sparks hope for new therapy

In a breakthrough, Australian researchers have developed a method to boost the immune system. This technique is seen to be capable of clearing an “HIV-like” infection from a mouse. This could in future lead to a cure for HIV and other chronic viral infections in humans. The findings from Melbourne’s Walter and Eliza Hall Institute are centred on a naturally occurring cell signalling hormone called interleukin-7 (IL-7).

6 Feb 2011

Cell signaling hormone boosts immune response to clear HIV-like infection

Australian scientists have successfully cleared a HIV-like infection from mice by boosting the function of cells vital to the immune response.

4 Feb 2011

Scientists unravel mystery about how new tumors in individuals with breast cancer take root

In a discovery that may lead to a new treatment for breast cancer that has spread to the bone, a Princeton University research team has unraveled a mystery about how these tumors take root.

4 Feb 2011

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

EGEN, Inc. today announced that the Food and Drug Administration (FDA) has awarded the company a four-year grant of $1,600,000 to assist in the Phase II clinical development of EGEN-001, the company's lead product. EGEN-001 is under clinical development for the treatment of advanced recurrent ovarian cancer.

2 Feb 2011

National Jewish Health scientists identify signaling pathway for ALI

Researchers at National Jewish Health have discovered a signaling pathway that is crucial to the devastating effects of acute lung injury. The data, obtained from cells, animals and ALI patients, suggest several potential therapeutic targets. Experimental blockade of one of the targets significantly reduced flooding of the lungs that is the hallmark of ALI.

31 Jan 2011